Next 10 |
home / stock / stro / stro articles
Sutro Biopharma Inc (NASDAQ:STRO) shares are trading lower by 2.8% to $5.18 during Tuesday’s session after the company announced the pricing ...
Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages ...
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth...
SOUTH SAN FRANCISCO, Calif., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage onco...
SOUTH SAN FRANCISCO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage onco...
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage onco...
PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Sutro Biopharma, Inc. (NASDAQ:STRO) ("Sutro"...
STAMFORD, Conn., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Abbott Cooper PLLC is investigating Sutro Biopharma, Inc. (NASDAQ:STRO) ("Sutro" or the "Comp...
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), a clinical-stage onco...
News, Short Squeeze, Breakout and More Instantly...
– Part 2 of REFRαME-O1, the registration-directed study of luvelta for patients with platinum-resistant ovarian cancer (PROC), is open for enrollment – – Planned 50 patients in Dose-Optimization (Part 1) of REFRαME-O1 have been enrolled and are in foll...
2024-04-03 17:00:02 ET Jay Olson from Oppenheimer issued a price target of $10.00 for STRO on 2024-04-03 14:01:00. The adjusted price target was set to $10.00. At the time of the announcement, STRO was trading at $5.09. The overall price target consensus is at $14.50 wit...
2024-04-03 08:00:08 ET Edward Tenthoff from Piper Sandler issued a price target of $11.00 for STRO on 2024-04-03 06:48:00. The adjusted price target was set to $11.00. At the time of the announcement, STRO was trading at $5.09. The overall price target consensus is at $1...